NVCR - Novocure Ltd

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $26.00 DETAILS

Stock News

Novocure Announces Upcoming Investor Events

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief Executive Officer, will take part in a fireside chat at 10:15 a.m. ET, as well as one-on-one meetings with investors. Morgan Stanley 24th Annual Global Healthcare Conference, September 14, 2026: Mr. Leonard and Christoph Brackmann, Chief Financial Officer, will take par.

Sep 02, 2026 03:00 AM • businesswire.com

Oncology firm Novocure says cyberattack exposed US patient records

Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed ‌internal records of more than 1,400 U.S. patients.

Sep 01, 2026 03:54 AM • reuters.com

Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Aug 28, 2026 06:55 AM • zacks.com

Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice

Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Aug 20, 2026 09:01 AM • zacks.com

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Aug 12, 2026 06:56 AM • zacks.com

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.

Aug 07, 2026 06:01 AM • zacks.com

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Jul 27, 2026 09:01 AM • zacks.com

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Jul 27, 2026 07:03 AM • zacks.com

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Jul 27, 2026 06:29 AM • zacks.com

NovoCure: Why I'm Fading The Q2 Earnings Rally

NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised to $0–$15M, yet true cash generation remains elusive. Optune Pax's early uptake is promising but too preliminary to signal sustainable growth; its Q2 contribution was just $1.6M.

Jul 24, 2026 09:45 AM • seekingalpha.com

NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)

Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability. NVCR's operating leverage is improving, with gross margins at 78% and net loss narrowing significantly, driven by 18% global active patient growth and expanding indications. Optune Pax's early launch shows promising adoption across academic and community settings, with repeat prescribing indicating potential for durable utilization and revenue upside.

Jul 24, 2026 06:21 AM • seekingalpha.com

NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript

Jul 23, 2026 09:00 AM • seekingalpha.com

NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates

NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.

Jul 23, 2026 05:16 AM • zacks.com

NovoCure Q2 Earnings Call Highlights

NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.

Jul 23, 2026 05:08 AM • marketbeat.com

Novocure Reports Second Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to exte

Jul 23, 2026 04:00 AM • gurufocus.com

Novocure Reports Second Quarter 2026 Financial Results

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure. “We continue to lau.

Jul 23, 2026 03:00 AM • businesswire.com

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jul 16, 2026 07:06 AM • zacks.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Jul 16, 2026 06:00 AM • prnewswire.com (Hide legal announcements)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Jul 14, 2026 02:24 PM • globenewswire.com (Hide legal announcements)

NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026

NovoCure Limited is downgraded from Strong Buy to Buy after the phase 3 TRIDENT trial failed to meet its primary endpoint of OS in newly diagnosed GBM patients. Company maintains growth potential with positive phase 2 PANOVA-4 results in mPDAC, ongoing KEYNOTE D58 trial in GBM, and an upcoming FDA decision for NSCLC brain metastases in Q4 2026. Q1 2026 net revenues rose 12% to $174 million, driven by Optune Gio, with full-year 2026 revenue guidance raised to $690–$710 million.

Jul 10, 2026 11:01 AM • seekingalpha.com